WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
FamiCord Acquires the Largest Stem Cell Bank in Portugal for $16.5M
FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
CryoHoldco Acquires Criocord, a Peruvian Cord Blood Bank and Cell Therapy Institute
CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. [Read more…]
Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More
With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.
However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.